TRIPLE NEGATIVE BREAST CANCER (TNBC)

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a PARP inhibitor (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early high-risk triple negative breast cancer that has a specific genetic marker (HRD positiv…

This study tests an experimental oral drug called Zn-Telomir in people with advanced or metastatic triple-negative breast cancer that has worsened after other treatments. The trial has two parts: first, finding a safe dose, then checking if the drug can shrink tumors. About 76 ad…

This study tests a two-drug combination (Sac-TMT and Tagitanlimab) in people with a specific type of advanced breast cancer called PD-L1-positive triple negative breast cancer that has been treated before. The goal is to see if the combination shrinks tumors or slows cancer growt…

This study tests whether adding the drug everolimus after standard chemotherapy can help prevent breast cancer from coming back in people with a specific type of triple-negative breast cancer called LAR. About 900 women who have had surgery for early-stage cancer will take part. …

This study tests a new drug, QLC5513, given alone or with another drug (QL1706) in people with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if the drugs can shrink tumors or slow the cancer's growth. About 60 wome…

This early-phase study tests whether adding pirfenidone to standard immunotherapy (camrelizumab) and chemotherapy can shrink tumors in 12 people with advanced triple-negative breast cancer. Participants must have already tried first-line treatment. The goal is to see how many pat…

This early-phase study tests a new drug called CT-202 in people with recurrent triple negative breast, colorectal, or urothelial cancers that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to check…

This early study tests a new radioactive drug called NTH-2403 in about 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The drug is designed to attach to a protein found on certain cancer cells and light them up on scans. The main goal i…

This study tests a nurse-led coping and support program called RESTORE for people who have finished treatment for triple-negative breast cancer. The goal is to see if the program is practical and helpful for reducing anxiety, fear of cancer returning, and improving quality of lif…

This study tracks 75 women with early-stage triple-negative breast cancer to see how chemotherapy combined with immunotherapy affects their ovaries and fertility. Participants will give blood samples and answer questionnaires before and after standard treatment, with follow-up fo…

This study will analyze tumor and blood samples from 200 women with early triple-negative breast cancer to find immune markers that predict whether immunochemotherapy works well. The goal is to understand why some patients have a complete response while others do not, which could…

This study aims to develop a blood test that can predict whether a patient with certain cancers (like lung, skin, or breast cancer) will benefit from immunotherapy. Researchers will analyze a specific type of white blood cell (neutrophils) from blood samples taken before treatmen…